Payment overview · 2025
General Payments
$781.05
42 reported records · 22 companies
Healthcare provider profile · identity verified
James Combs, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · GILBERT, AZ · NPI 1265455331
Verified facts
What the public records show
CMS Open Payments records show James Combs, PA received $781.05 in general payments during 2025 across 42 reported records.
Astellas Pharma US Inc accounted for 8.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $65.68 | 8.4% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $65.57 | 8.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.59 | 8.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.25 | 8.1% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $61.22 | 7.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.20 | 7.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $54.94 | 7.0% | 3 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $43.57 | 5.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.82 | 4.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.09 | 4.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.18 | 3.9% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $28.75 | 3.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.24 | 3.6% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $21.10 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.22 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.03 | 2.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.48 | 2.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.10 | 2.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.15 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.82 | 2.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.32 | 2.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.73 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $781.05 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $65.68 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $65.57 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.25 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $61.22 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $54.94 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $54.94 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $46.90 | 3 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $43.57 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $43.57 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.96 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.96 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.82 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.24 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 156 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 144 | 40 |
| Azithromycin | Azithromycin | 124 | 104 |
| Lisinopril | Lisinopril | 113 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 107 | 30 |
| Losartan Potassium | Losartan Potassium | 105 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 12 |
| Gabapentin | Gabapentin | 75 | 17 |
| Alprazolam | Alprazolam | 74 | 14 |
| Metformin Hcl | Metformin Hcl | 70 | 20 |
| Omeprazole | Omeprazole | 69 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 16 |
| Simvastatin | Simvastatin | 61 | 18 |
| Atenolol | Atenolol | 59 | 18 |
| Methylprednisolone | Methylprednisolone | 53 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 13 |
| Trazodone Hcl | Trazodone Hcl | 48 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 15 |
| Tramadol Hcl | Tramadol Hcl | 42 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 36 |
| Potassium Chloride | Potassium Chloride | 41 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 13 |
| Ibuprofen | Ibuprofen | 39 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 11 |
| Cephalexin | Cephalexin | 30 | 19 |
| Prednisone | Prednisone | 30 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 15 |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 12 |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Furosemide | Furosemide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Famciclovir | Famciclovir | 12 | 11 |
| Glimepiride | Glimepiride | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $781.05 · 42 records | Astellas Pharma US Inc | ABRYSVO, ACCRUFER, CAPVAXIVE, COMIRNATY, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, LEQVIO, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRINTELLIX, Tymlos, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error